Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
<p>Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>
保存先:
| 第一著者: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| その他の著者: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| 出版事項: |
2025
|
| 主題: | |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
類似資料
-
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025) -
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
著者:: Anna Starshinova (22571846)
出版事項: (2025)